REGENXBIO: Key FDA Decision On Hunter Syndrome Just Weeks Away [Seeking Alpha]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Seeking Alpha
RGX-121 offers a unique CNS-targeted approach for Hunter syndrome, with strong biomarker and neurodevelopmental data supporting its accelerated approval case ahead of the February 8 PDUFA date. RGNX's valuation appears modest at a 3.3x forward EV/sales multiple, with late-stage assets, near-term regulatory events, and a healthy cash position providing balance sheet flexibility. Risks include reliance on surrogate endpoints, small pivotal trial sizes, and FDA skepticism, but multiple upcoming catalysts and partnership milestones with AbbVie present significant upside. Miyako Nakamura/E+ via Getty Images Thesis Recently, we got an update from Regenxbio Inc. ( RGNX ). Management highlighted 2026 as a make-or-break year for the company, and I'm inclined to agree. If you look at it, there are quite a few near-term regulatory and clinical catalysts that This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the co
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law FirmBusiness Wire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNXGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNXPR Newswire
- Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA ActionPR Newswire
- REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
RGNX
Earnings
- 11/6/25 - Beat
RGNX
Sec Filings
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- 1/29/26 - Form 4
- RGNX's page on the SEC website